ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD a Vlastimil VÁLEK. Endoluminal radiofrequency ablation of malignant biliary stenoses. In European Congress of Radiology 2015. 2015. ISSN 1869-4101. Dostupné z: https://dx.doi.org/10.1007/s13244-015-0387-z.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Endoluminal radiofrequency ablation of malignant biliary stenoses
Autoři ANDRAŠINA, Tomáš (703 Slovensko, garant, domácí), Jiří PÁNEK (203 Česká republika, domácí), Jan HLAVSA (203 Česká republika, domácí), Vladan BERNARD (203 Česká republika, domácí) a Vlastimil VÁLEK (203 Česká republika, domácí).
Vydání European Congress of Radiology 2015, 2015.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30000 3. Medical and Health Sciences
Stát vydavatele Rakousko
Utajení není předmětem státního či obchodního tajemství
Kód RIV RIV/00216224:14110/15:00087460
Organizační jednotka Lékařská fakulta
ISSN 1869-4101
Doi http://dx.doi.org/10.1007/s13244-015-0387-z
Klíčová slova anglicky endoluminal ablation biliary
Štítky EL OK
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 6. 4. 2016 12:33.
Anotace
Purpose: To prove efficacy of endoluminal radiofrequency ablation before stenting of malignant biliary stenoses. Methods and Materials: 54 patients with histologically proven malignant biliary stenoses have been enrolled in a prospective randomised study from 2010. 73 non-covered self-expandable metal stents were inserted. In group A (n=22) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB;EMcision Ltd.,London,UK) was performed 0-48hours prior to the stent insertion, in group B (n=32) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meyer analysis). Results: No major complications related to the stent insertion and endoluminal ablation were recorded. 30 day mortality was 3.7%. The average primary stent patency was 5.6 and 5.2 months in group A and B, respectively, 3-months and 6-months stent failure was 9.1% and 13.6% in group A and 15% and 25% in group B. The median survival from the insertion of the stent was 5.9 (2.9-6.7) and 5.4 (3.7-8.6) months, the median survival from the initial drainage was 9.6 (5.6-12.2) and 8.5 (5.8-12.7) months in group A and B, respectively. The difference was not statistically significant. Conclusion: In the prospective randomised clinical study the effect of an endoluminal ablation on patients survival was not proven. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. In addition, the intervention was not associated with higher rates of complications.
Návaznosti
NT14586, projekt VaVNázev: Choledochoskopem navigovaná radiofrekvenční ablace žlučových cest.
Investor: Ministerstvo zdravotnictví ČR, Choledochoskopem navigovaná radiofrekvenční ablace žlučových cest.
VytisknoutZobrazeno: 25. 4. 2024 13:52